The global Preventive Vaccine market was valued at USD 38.42 Billion in 2022 and is projected to reach USD 71.14 Billion by 2030, registering a CAGR of 9.2% for the forecast period 2023-2030.
Preventive vaccinations are an important part of public health because they protect against infectious diseases by activating the immune system to recognize and fight certain microorganisms. These vaccines function by injecting into the body harmless bits of a virus or bacteria, or weakened/deactivated forms of the pathogen. This exposure causes the immune system to make antibodies and form an immunological memory, allowing it to detect and respond quickly to the actual infectious agent if it is encountered again in the future. Preventive vaccines have been critical in eradicating or greatly lowering the prevalence of various illnesses around the world, saving millions of lives and averting illness and disability. They are available for a wide range of diseases, from childhood illnesses like measles and polio to seasonal influenza and newer dangers like COVID-19, providing people and populations with critical protection against diverse infectious threats.
- 2022: USD 38.42 billion
- 2030: USD 71.14 billion
- CAGR (2023-2030): 9.2%
Preventive Vaccine Market Dynamics
Drivers Propelling the Demand for Preventive Vaccine include:
Growing infectious diseases is driving the market:
The increased prevalence of infectious diseases is a significant driving force in the market for preventative vaccines. The demand for vaccinations grows as infectious diseases develop, mutate, or emerge as new dangers. Infectious illness spread is aided by factors such as greater globalization, urbanization, climate change, and antibiotic resistance. This increase emphasizes the critical importance of effective preventive measures, with vaccines serving as one of the most powerful tools in disease prevention and control. With a growing global population and increased interconnectedness, there is a greater demand for vaccines against both traditional and emerging infectious diseases, compelling pharmaceutical companies, governments, and healthcare organizations to invest in vaccine research, development, and distribution to address these evolving threats. As a result, this tendency pulls the preventive vaccine market forward as it seeks to stay up with the changing landscape of infectious illnesses and fulfill the increasing demand for effective preventative measures.
For instance, in December 2023, Shionogi announced a collaboration with SOBI on Fetcroja to provide access for people with infections caused by aerobic Gram-negative organisms who have few treatment alternatives.
In August 2023, Pfizer's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth to six months of age through active immunization of pregnant women between 32- and 36-weeks’ gestation.
In October 2023, Pfizer's vaccines to help protect against the five most common meningococcal serogroups that cause the majority of invasive meningococcal disease (IMD) globally, PENBRAYA combines the components of two meningococcal vaccines, Trumenba (meningococcal group B vaccine) and Nimenrix (meningococcal groups A, C, W-135, and Y conjugate vaccine).
Vaccine apprehension and misinformation may hamper the market growth:
The proliferation of disinformation and vaccine reluctance pose serious obstacles to the preventative vaccine business. Skepticism or refusal to vaccinate, fueled by disinformation, myths, or skepticism in vaccine safety and efficacy, causes roadblocks to high immunization rates. This reluctance has an effect on the market by lowering the uptake of existing vaccinations and influencing the release of new ones. Misinformation travels readily via social media and other avenues, seeding doubts about the safety, necessity, or potential side effects of vaccines, leading to a loss of trust in vaccination programs. As a result, decreased vaccination rates can lead to higher disease outbreaks, which not only endanger public health but also have an impact on market growth by impeding broad use of preventative vaccinations and dampening investment in vaccine development and distribution efforts. Addressing vaccine apprehension and dispelling misinformation are critical for sustaining market growth and assuring the efficacy of preventative immunization programs. Efforts to convey correct information, raise public knowledge, and foster faith in vaccines are critical to overcome these obstacles.
Stringent regulatory processes can put up various challenges:
Stringent regulatory processes pose a substantial impediment to the market for preventive vaccines. While laws ensure safety, efficacy, and quality control, the lengthy and stringent approval processes can cause new vaccines to be introduced to the market late. Developing and testing vaccines necessitates rigorous clinical studies, data analysis, and regulatory reviews, all of which take a significant amount of time and money. Regulatory organizations' severe standards aim to ensure vaccine safety and effectiveness, but they can also create roadblocks for manufacturers, thereby impeding the pace of vaccine discovery and release. Furthermore, differences in regulatory frameworks between regions or countries can complicate the process by needing vaccine makers to navigate numerous sets of rules and comply with varying standards, which can be time-consuming and costly. To stimulate innovation and timely access to effective vaccines while maintaining the highest safety standards, it is critical to balance the requirement for stringent safety measures with streamlined, efficient regulatory processes. Efforts to shorten regulatory routes and encourage international collaboration among regulatory agencies can help reduce these issues and speed vaccine availability to address growing infectious threats.
Emerging technologies offering new opportunities for the Preventive Vaccine market:
Emerging technologies, which are transforming vaccine development, manufacture, and distribution, create significant prospects for the preventive vaccine business. Biotechnology advances, such as mRNA and vector-based platforms, have facilitated the rapid synthesis of vaccinations, as demonstrated by the astonishingly quick creation of COVID-19 vaccines. These technologies provide more flexible and scalable vaccine production methodologies, allowing for faster adaption to new strains or developing infectious illnesses. Furthermore, advancements in delivery techniques, such as microneedle patches and needle-free injectors, improve vaccine administration, thereby increasing accessibility and patient acceptance. Furthermore, data analytics and artificial intelligence (AI) play an important role in vaccine research and development, assisting in the identification of vaccine candidates and optimizing manufacturing processes, streamlining and accelerating the entire vaccine development lifecycle. Embracing these emerging technologies has the potential to change vaccine development, making it more flexible, adaptive, and responsive to changing global health concerns.
|Market Size in 2022
|USD 38.42 Billion
|Market Forecast in 2030
|USD 71.14 Billion
|Compound Annual Growth Rate (CAGR)
|Revenue (USD Million) and Volume (Kilo Tons)
|By Type, By Infection Type, By Administration Mode, By End-User, & By Region
|By Infection Type
|2018 - 2022
|2023 - 2030
Segment Analysis of the Preventive Vaccine Market
The Preventive Vaccine’ market is segmented by type, by infection type, by administration mode, by end-user, & by region.
The Preventive Vaccine market based on the segment type is classified into multivalent vaccines, monovalent vaccines. The monovalent vaccines segment to hold major share during the forecast period. These vaccines target a single pathogen and provide immunity against that pathogen. They have historically been common and frequently used in the treatment of infectious disorders including as measles, mumps, rubella, and hepatitis. The popularity of monovalent vaccines stems from their targeted efficacy, proven safety profiles, and significant research and development, all of which contribute to their market dominance. While multivalent vaccinations, which can target numerous illnesses in a single formulation, have their advantages, monovalent vaccines remain critical in giving precise and focused immunity against individual pathogens, leading to their dominant position in the vaccine market.
By Administration Mode
The intramuscular & subcutaneous segment to hold major share during the forecast period:
Based on the administration mode segment the market for Preventive Vaccine is classified into oral, intramuscular & subcutaneous, others. The intramuscular & subcutaneous segment to hold major share during the forecast period the segments growth can be attributed as vaccines given intramuscularly or subcutaneously frequently elicit strong immune responses, ensuring the body's excellent protection against a variety of diseases. When compared to other forms of administration, these routes allow for the delivery of higher volumes and are recognized for provoking powerful and long-lasting immune responses. Numerous vaccines, including those against influenza, measles, hepatitis, and tetanus, have been administered using these traditional and favored ways. Their familiarity, combined with the comfort and experience of healthcare providers in giving vaccines via these routes, contributes greatly to their market domination. While other modes of administration, such as oral vaccines, have advantages such as convenience of administration, intramuscular and subcutaneous methods remain important because to their proven efficacy and popular acceptability.
North America holds the largest share during the forecasted period:
The North America to be the largest market share during the forecasted period. The region has modern healthcare infrastructure, strong research and development skills, and a high degree of vaccine awareness and acceptability among its population. Furthermore, strict regulatory frameworks ensure vaccine safety and efficacy, instilling trust in both healthcare professionals and the general population. The existence of major pharmaceutical corporations, as well as considerable government funding for immunization programs, reinforces North America's vaccine market supremacy. Furthermore, the region's proactive response to outbreaks, along with a higher disposable income, adds to increased vaccination accessibility and adoption, establishing North America as a prominent player in the worldwide preventive vaccine market.
List of the prominent players in the Preventive Vaccine Market:
Merck & Co. Inc.,
Johnson & Johnson,
Daiichi Sankyo Company Limited,
Panacea Biotec Ltd.,
Serum Institute of India Pvt. Ltd.,
Mitsubishi Tanabe Pharma Corporation,
Emergent BioSolutions Inc.,
Bavarian Nordic A/S.
Segmentation Analysis of the Preventive Vaccine Market
- Multivalent Vaccines
- Monovalent Vaccines
- Covid 19
- Intramuscular & Subcutaneous
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
The COVID-19 pandemic has had a significant impact on the preventative vaccine market, sparking remarkable upheavals and advances. The virus's urgency fueled an unprecedented global effort toward vaccine development, culminating in the rapid production and emergency approval of numerous COVID-19 vaccines. This compressed timescale demonstrated the potential for rapid vaccine development and deployment, establishing a new standard for future infectious disease responses. The pandemic also raised public awareness of the importance of vaccines in limiting illness transmission and protecting communities.
Furthermore, the pandemic prompted enormous expenditures in vaccine research, manufacturing, and distribution infrastructure, altering the vaccine development environment. Collaborations between governments, pharmaceutical corporations, and research institutes became more intense, resulting in advancements in vaccination technologies and manufacturing procedures. However, discrepancies in access were highlighted by the uneven distribution of vaccines globally, underscoring the need for equitable vaccine distribution and addressing healthcare inequality. Lessons from the COVID-19 pandemic are poised to influence the future of the preventive vaccination market, spurring continuous innovation, collaboration, and initiatives to ensure greater accessibility and equity in vaccine delivery globally.